705 CHARACTERISING OLDER ADULTS' RISK OF HARM FROM BLOOD-PRESSURE LOWERING MEDICATIONS: A SUB-ANALYSIS FROM THE PRIME STUDY. (8th March 2022)

• Record Type: Journal Article
• Authors: Hussain, A S; Ali, K; Parekh, N; Stevenson, J M; Davies, J G; Bremner, S; Rajkumar, C
• Is Part Of: Age and ageing. Volume 51(2022)Supplement 1
• Publication Date: 2022-03-08
• Subjects: Aging -- Periodicals; Geriatrics -- Periodicals; 618.97
• DOI: 10.1093/ageing/afac035.705
• Languages: English
• ISSNs: 0002-0729

Abstract

Abstract: Introduction: Hypertension is a major risk factor for cardiovascular disease and death. Randomised trials in older adults with relatively few co-morbidities recommend treatment of their hypertension [1]. However, blood-pressure lowering medications increase the risk of medication-related harm (MRH) from adverse drug reactions (ADRs), non-adherence, medication errors and drug–drug interactions. We aimed to identify characteristics associated with MRH in older people on blood-pressure lowering medications. Method: The PRIME (prospective study to develop a model to stratify the risk of MRH in hospitalized elderly patients in the UK) study investigating the incidence and cost of MRH in 1280 older people in Southern England [2]. Adults ≥65 years were recruited from five teaching hospitals at hospital discharge and followed up for 8-weeks. Telephone interviews with study participants, review of primary care records and hospital readmissions were undertaken to identify MRH. PRIME study participants taking blood-pressure lowering medications, as defined by National Institute for Health and Care Excellence hypertension guidelines [3], were included in this analysis. Results: Sixty-six percent of the PRIME cohort (n = 841) were taking blood-pressure lowering medications. Patients on four blood-pressure lowering medications were five times more likely to experience MRH compared to those taking just one medication (OR 4.96; 95%CI 1.63-15.13;p = 0.01). Most harm events were serious (80%, n = 123), requiring dose change or treatment cessation. Most MRH cases were potentially preventable (49%, n = 75). Conclusion: MRH from blood-pressure lowering medication in older people is common, serious, and potentially preventable. Decisions around maximising cardiovascular risk reduction must be carefully considered in the context of MRH from blood-pressure lowering medications. References: 1. Sheppard JP, Lown M, Burt J et al. Generalizability of blood pressure lowering trials to older patients: cross‐sectional analysis. J Am Geriatr Soc 2020; 68: 2508–15. 2. Parekh N, Ali K, Stevenson JM et al. Incidence and cost of medication harm in older adults following hospital discharge: a multicentre prospective study in the UK. Br J Clin Pharmacol 2018; 84: 1789–97. 3. National Institute for Health and Care Excellence (2019). Available at https://www.nice.org.uk/guidance/ng136 . Accessed 27/11/2020.